MD Anderson
MD Anderson, Blueprint Medicines Team Up to Bring CDK2 Inhibitor BLUE-222 to the Clinic
Through a three-year partnership, MD Anderson's Therapeutics Discovery division will help Blueprint ID cancers susceptible to BLU-222 and biomarkers of response.
Hummingbird Bioscience, MD Anderson Partner to Study VISTA Checkpoint Inhibitor
Within the collaboration, the company will leverage MD Anderson's immune profiling resources to identify biomarkers predictive of outcomes to HMBD-002.
Cyclacel Pharmaceuticals Doses First Patient in CDK2/9 Inhibitor Basket Trial
The firm will evaluate fadraciclib as a monotherapy for patients with certain solid tumors and lymphomas in the Phase I/II registration-directed trial.
Nucleix, MD Anderson Partner on Methylation-Based Lung Cancer Dx Tests
The collaborators will initially evaluate methylation markers that they believe are important for characterizing lung cancer subtypes.
MD Anderson Cancer Center, Refuge Biotechnologies Partner on Engineered TIL, CAR T-Cell Therapies
The collaboration gives MD Anderson exclusive rights to Refuge's cell engineering platform, which the partners plan to use to improve TIL therapies.
Mar 25, 2021